EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Challenges and strategies in the soluble expression of CTA1-(S14P5)4-DD and CTA1-(S21P2)4-DD fusion proteins as candidates for COVID-19 intranasal vaccines

Simson Tarigan iD, Gita Sekarmila, Apas, Sumarningsih, Ronald Tarigan, Riyandini Putri, Damai Ria Setyawati

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Simson Tarigan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Organization for Health, National Research and Innovation (BRIN), Cibinong, Indonesia. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Administration, Intranasal, Solubility, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Direktorat Jenderal Penguatan Riset dan Pengembangan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing intranasal vaccines against pandemics and devastating airborne infectious diseases is imperative. The superiority of intranasal vaccines over injectable systemic vaccines is evident, but developing effective intranasal vaccines presents significant challenges. Fusing a protein antigen with the catalytic domain of cholera toxin (CTA1) and the two-domain D of staphylococcal protein A (DD) has significant potential for intranasal vaccines. In this study, we constructed two fusion proteins containing CTA1, tandem repeat linear epitopes of the SARS-CoV-2 spike protein (S14P5 or S21P2), and DD. Structural predictions indicated that each component of the fusion proteins was compatible with its origin. In silico analyses predicted high solubility for both fusion proteins when overexpressed in Escherichia coli . However, contrary to these predictions, the constructs exhibited limited solubility. Lowering the cultivation temperature from 37°C to 18°C did not improve solubility. Inducing expression with IPTG at the early log phase significantly increased soluble CTA1-(S21P2)4-DD but not CTA1-(S14P5)4-DD. Adding non-denaturing detergents (Nonidet P40, Triton X100, or Tween 20) to the extraction buffer significantly enhanced solubility. Despite this, purification experiments yielded low amounts, only 1–2 mg/L of culture, due to substantial losses during the purification stages. These findings highlight the challenges and potential strategies for optimizing soluble expression of CTA1-DD fusion proteins for intranasal vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsAdministration, IntranasalSolubilityCOVID-19 VaccinesCholera ToxinSARS-CoV-2COVID-19HumansSpike Glycoprotein, CoronavirusEscherichia coliAnimals

Substanzen

Recombinant Fusion ProteinsCOVID-19 VaccinesCholera ToxinSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Research Organization for Health, National Research and Innovation (BRIN), Cibinong, Indonesia.
  • School of Veterinary and Medical Sciences, IPB University, Bogor, Indonesia.

ORCID-Profile: Simson Tarigan

Förderung

  • Direktorat Jenderal Penguatan Riset dan Pengembangan

Zitieren

APA

Tarigan, S., Sekarmila, G., Apas, Sumarningsih, Tarigan, R., Putri, R., & Setyawati, D. R. (2024). Challenges and strategies in the soluble expression of CTA1-(S14P5)4-DD and CTA1-(S21P2)4-DD fusion proteins as candidates for COVID-19 intranasal vaccines. PLOS ONE. https://doi.org/10.1371/journal.pone.0306153

Vancouver

Tarigan S, Sekarmila G, Apas, Sumarningsih, Tarigan R, Putri R, et al. Challenges and strategies in the soluble expression of CTA1-(S14P5)4-DD and CTA1-(S21P2)4-DD fusion proteins as candidates for COVID-19 intranasal vaccines. PLOS ONE. 2024. doi:10.1371/journal.pone.0306153

BibTeX
@article{Tarigan2024,
  author = {Tarigan, Simson and Sekarmila, Gita and Apas and Sumarningsih and Tarigan, Ronald and Putri, Riyandini and Setyawati, Damai Ria},
  title = {Challenges and strategies in the soluble expression of CTA1-(S14P5)4-DD and CTA1-(S21P2)4-DD fusion proteins as candidates for COVID-19 intranasal vaccines},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306153}
}
Kostenlos starten →